News
The Peptide Index™: August 2026 rankings update
Apex Peptides holds the top position; Cascade Research Group drops 17 points after failed verification; BioRegen enters the top five.
Latest From The Institute
Everything we’ve just published.
Research analysis, industry news, original investigations and education — published continuously by the Institute’s newsroom and testing desk.
More From The Institute
New study explores oral delivery of GLP-1 peptides
Absorption enhancers push oral bioavailability past thresholds previously considered impractical for large peptides.
Research
Major lab raises concerns about peptide purity industry-wide
An analytical laboratory serving the research-chemical sector reports rising failure rates across client samples.
Industry
We Independently Tested 20 Peptide Samples. Here’s What We Found.
Six months, three laboratories, and 20 anonymously purchased samples from 12 companies. Purity ranged from 61% to 99.2% — and two products failed verification entirely.
Special Report
How to read a certificate of analysis — and how to spot a fake one
A COA is only as good as the laboratory behind it. A practical walkthrough of chromatograms, mass-spec traces, and red flags.
EducationSemaglutide content verification: 2026 mid-year testing summary
Seven semaglutide specimens tested this year: six verified, one 14% under label.
Lab InsightsForum roundup: the reconstitution questions our community answers best
The community’s highest-signal threads this month, with the claims checked against published stability data.
Community
Why we publish failed tests — and what happens after we do
Disputes, retests, legal letters, and score consequences: the afterlife of a failed verification.
Transparency
The GLP-1 gray market after compounding: where the supply went
As legal compounding contracted, demand moved to research-chemical channels. We tracked availability, pricing, and quality across 40 listings.
InvestigationSemaglutide vs. tirzepatide: what head-to-head data shows
SURMOUNT-5 and real-world cohorts consistently favor the dual agonist on weight endpoints — with nuances the headlines skip.
ResearchUnderstanding peptide reconstitution: concentrations, diluents, and stability windows
The chemistry behind reconstitution choices, and what published stability data actually covers.
EducationWhat "pharmaceutical grade" actually means — and what it legally doesn’t
The most abused phrase in peptide marketing, unpacked.
EducationGHK-Cu research review: skin, hair, and the injectable evidence gap
Strong topical literature, thin injectable data — a compound with a genuinely split evidence base.
ScienceClinical trial tracker: peptide and GLP-1 programs to watch in late 2026
Phase 3 readouts, new obesity candidates, and the muscle-preservation programs entering the clinic.
Clinical TrialsCommunity testing patterns: what 400 user reports tell us about fulfillment
Aggregated consumer reports show delivery times improving — and two companies driving most complaints.
CommunityIpamorelin and CJC-1295: what stacked GH-axis research actually measures
The synergy claim has real pharmacology behind it — and important measurement caveats.
ScienceState pharmacy boards begin coordinated action on gray-market GLP-1 sales
Six states announce parallel enforcement; more expected to follow.
RegulationPT-141 underdosing: a pattern across three companies
Every PT-141 product we have tested since 2025 measured under label. The shortfalls cluster suspiciously.
InvestigationMOTS-c and mitochondrial peptides: an emerging research class
Peptides encoded in mitochondrial DNA are rewriting assumptions about the genome’s smallest products.
ScienceHow The Peptide Institute tests products: our laboratory methodology, in full
Anonymous purchasing, chain of custody, laboratory selection, and how results feed the Index Score.
MethodologyEpitalon and the replication problem in longevity peptides
Decades of source-country research, near-zero independent replication: how to weigh geographically concentrated evidence.
ScienceTesamorelin: the approved GHRH analog most researchers overlook
A full FDA approval, phase 3 visceral-fat data, and lessons for evaluating its gray-market cousins.
ScienceThe economics of independent testing: why almost nobody does it
What a single verified test actually costs, and why review sites so rarely test anything.
TransparencySelank and Semax: evaluating the Russian clinical peptides
Approved in one country, unstudied in most others — a framework for reading asymmetric evidence.
ScienceCold-chain shipping study: temperature logging across 12 suppliers
We shipped temperature loggers with orders from every indexed company. Summer transit told a clear story.
Lab InsightsAOD-9604: when a compound outlives its failed trials
The obesity program failed in 2007. The marketing never stopped. A case study in zombie evidence.
ScienceThe Peptide Institute Weekly
Research. Testing. Regulation. No hype.
One email a week: new study summaries, the latest independent lab results, ranking movements, and regulatory developments that matter.
- New research, summarized in plain English
- Independent lab results as they publish
- Score and ranking movements